Change NICE negative nivolumab recommendation; every voice counts

We still have time to change NICE negative nivolumab recommendation.

Many of you may be aware that the immunotherapy drug nivolumab is currently being appraised by NICE for the treatment of advanced kidney cancer. Everyone at KCUK is hoping that this drug will be approved and be available to people on the NHS this autumn. We wanted to inform people who are interested in the nivolumab appraisal by NICE that the document which was written based on the first committee meeting has been published on their website.
https://www.nice.org.uk/guidance/GID-TA10037/documents/appraisal-consultation-document
We understand that not everyone who follows our blog will want to spend their time and energy on reading documents but for those who want to find out more about the treatments for advanced kidney cancer (if the tumour has spread to another part of the body) and the nivolumab appraisal the opportunity is there.
If you feel very strongly about the success of the nivolumab appraisal we would like to let you know that anyone can comment on the recent NICE appraisal consultation document. Please follow the link below to the area on the NICE website where you can comment on the appraisal. You will need to create a NICE account/sign in to comment but anyone is entitled to do so. The deadline for comments is the 26^th July. Every voice counts.
https://www.nice.org.uk/guidance/indevelopment/GID-TA10037/consultation/html-content
We feel that the nivolumab appraisal committee need to hear that there is an unmet need for patients with advanced kidney cancer.  That people need more drug options, especially for drugs that work in a very different ways and offer hope if people become resistant to current medication. KCUK will be commenting on the appraisal consultation document but welcome you to make your voice heard if you wish to.